The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor

Clinical Neurosurgery

Volumn 56, Issue , 2009, Pages 98-106

  Heimberger, Amy B ^a   Kong, Ling Yuan ^a   Abou Ghazal, Mohamed ^a   Reina Ortiz, Chantal ^a   Yang, David S ^a   Wei, Jun ^a   Wei, Qiao ^a   Schmittling, Robert J ^a   Archer, Gary E ^a   Sampson, John H ^a   Hiraoka, Nobuyoshi ^a   Priebe, Waldemar ^a   Fuller, Gregory N ^a   Sawaya, Raymond ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; JANUS KINASE; PEPTIDE VACCINE; PROTEIN INHIBITOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; WP 1066; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; TYRPHOSTIN; WP1066;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG MECHANISM; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; COHORT ANALYSIS; CULTURE TECHNIQUE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ANIMALS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED C57BL; PYRIDINES; RETROSPECTIVE STUDIES; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TYRPHOSTINS;

EID: 77952295844     PISSN: 00694827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-K, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB: The incidence, correlation with tumor infiltrating inflammation, and prognosis of p-STAT3 expression in human gliomas. Clin Cancer Res 14: 8228-8235, 2008.
2. Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalban C, Piris MA: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11:1467-1473, 2005.
3. Andaloussi AE, Lesniak MS: An increase in CD4+CD25+FOXP3 + regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-Oncology 8:234-243, 2006.
4. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB: CYP1B1 expression in glial cell tumors: An immunotherapeutic target. Clin Cancer Res 13:3559-3567, 2007.
5. Brooks WH, Markesbery WR, Gupta GD, Roszman TL: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4:219-224, 1978.
6. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, Madden T, Priebe W: A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. Presented at the 98th American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 16, 2007.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004.
8. Dey M, Hussain SF, Heimberger AB: The role of glioma microenvironment in immune modulation: Potential targets for intervention. Lett Drug Des Discov 3:443-451, 2006.
9. El Andaloussi A, Lesniak MS: CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 83:145-152, 2007.
10. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294-3302, 2006.
11. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158-2167, 2007.
12. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH: Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12:4294-4305, 2006.
13. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z: WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67:11291-11299, 2007.
14. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593, 2007.
15. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344, 2004.
16. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648, 2007.
17. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 12:3355-3360, 2006.
18. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W: WP1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. Presented at 98th American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 16, 2007.
19. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50:158-164; discussion 164-166, 2002.
20. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247-4254, 2003.
21. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466, 2005.
22. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 11:267-272, 2005.
23. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14: 5166-5172, 2008.
24. Hiraoka N, Onozato K, Kosuge T, Hirohashi S: Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434, 2006.
25. Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: Clinical implications. Clin Cancer Res 13:1362-1366, 2007.
26. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB: A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67:9630-9636, 2007.
27. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 8:261-279, 2006.
28. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26:2435-2444, 2007.
29. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB: Preferential migration of regulatory T cells mediated by glioma- secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123-131, 2008.
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
31. Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T, Yoshimura A: Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 203:1021-1031, 2006.
32. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902-911, 2007.
33. Kong L-K, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB: A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58:1023-1032, 2009.
34. Kong L-Y, Kapuria V, Bartholomeusz G, Talpaz M, Priebe W, Donato NJ: Antitumor activity and mechanism of action of a novel Stat3 inhibitor, WP1066, against human B-cell non-Hodgkin's lymphoma and multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106:1489, 2005.
35. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB: A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14:5759-5768, 2008.
36. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321, 2005.
37. Kortylewski M, Yu H: Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131-139, 2007.
38. Kupferman ME, Zhou G, Zhao M, Jasser S, Dakak-Yazici Y, Priebe W, Myers JN: A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. Presented at 97th American Association of Cancer Research Annual Meeting, Washington, DC, April 3, 2006.
39. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761, 2002.
40. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966.
41. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438-448, 1988.
42. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, Pisa P: CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177:7398-7405, 2006.
43. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-4425, 1997.
44. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457-2464, 2005.
45. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915, 2004.
46. Safdari H, Hochberg FH, Richardson EP Jr: Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 23: 221-226, 1985.
47. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad SciUSA 102:18538-18543, 2005.
48. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE 2nd, Friedman HS, Bigner DD, Sampson JH: Detection of humoral response in patients with glioblastoma receiving EGFRvIII- KLH vaccines. J Immunol Methods 339:74-81, 2008.
49. Snedecor GW, Cochran WG: Statistical Methods. Ames, Iowa State University Press, 1980.
50. Strik HM, Stoll M, Meyermann R: Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 24:37-42, 2004.
51. von Hanwehr RI, Hofman FM, Taylor CR, Apuzzo ML: Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60:1138-1147, 1984.
52. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766-4772, 2001.
53. Yu H, Jove R: The STATs of cancer-New molecular targets come of age. Nat Rev Cancer 4:97-105, 2004.
54. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51, 2007.
55. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J: IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571-1579, 2006.